Lidocaine 5% ointment 35.44GM
Ended Awarded Last action
- Contract number
- SPE2DR26FJGS5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,086
Award facts
- Contract value 100% obligated
- $1,085.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,085.84 to DMS Pharmaceutical Group Inc. on January 5, 2026, for the supply of Lidocaine 5% Ointment in 35.44-gram units. This firm fixed-price delivery order, designated as contract 4570480141, carries an ultimate completion date of January 6, 2026, and does not include a set-aside designation. The work will be performed in Park Ridge, Illinois, where DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is headquartered. DMS Pharmaceutical Group has been registered in the System for Award Management since July 2001 and serves as a critical supplier within the federal pharmaceutical supply chain, particularly for the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, and positions the company as one of multiple regional prime vendor contractors within the broader $30.3 billion PPV-G GEN V acquisition strategy. The IDC structure authorizes DLA to issue firm fixed-price delivery orders for an extensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables, to support Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FJGS5?
SPE2DR26FJGS5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FJGS5 worth?
The government has obligated $1,086 on SPE2DR26FJGS5.
Is contract SPE2DR26FJGS5 an order under another contract?
Yes. SPE2DR26FJGS5 is a delivery order under SPE2DR25D9150, an indefinite delivery contract.
Was contract SPE2DR26FJGS5 competed?
The extent of competition for SPE2DR26FJGS5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award